NRSN: NeuroSense Therapeutics, Ltd. Projected Future Earnings
High costs and dependence on clinical trial outcomes create significant risks for NeuroSense Therapeutics (NRSN). However, the development of a unique ALS treatment will provide the firm with monopoly pricing power over the therapy. The company's profit expectations demonstrate that the parameter value is , while the research center in Israel optimizes drug production through external CDMO partners.
Metric breakdowns and analytics for NeuroSense Therapeutics, Ltd. (NRSN)
- price and consensus price forecast:
- market capitalization information:
- book capitalization indicators:
- issuer credit burden and liquidity indicators:
Debt to Equity NeuroSense Therapeutics|NRSN - Long-Term Liabilities to Capital|Short-Term Debt to Equity NeuroSense Therapeutics Ltd.|NRSN - Company Total Debt Obligations|Debts to Book Capitalization NeuroSense Therapeutics|NRSN - Long-Term Debt|Company Short-Term Debt NeuroSense Therapeutics|Quick Liquidity neurosense-tx.com
- earnings and market ratios statistics:
NRSN - Net Financial Result|Projected Future Earnings NeuroSense Therapeutics|NRSN - Market Cap to Earnings|Projected Price to Earnings neurosense-tx.com|NRSN - Growth-Adjusted Payback Ratio|Enterprise Value to EBITDA Ratio NeuroSense Therapeutics|NRSN - Company profit before taxes, interest and amortization|Net earnings per share (EPS TTM) NeuroSense Therapeutics|NRSN - Earnings per share for the trailing year|Quarterly EPS earnings growth neurosense-tx.com|NRSN - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year NeuroSense Therapeutics
- revenue and sales proceeds data:
Initial company analysis:NeuroSense Therapeutics, NRSN
The indicator is calculated as the difference between projected revenue and total operating expenses. It measures the business's actual capacity to generate income while neutralizing inflationary pressure on costs. At NeuroSense Therapeutics (NRSN), grant transparency and strict compliance ensure these calculations are highly reliable. By analyzing this forward-looking financial metric, investors can filter out management's informational noise, although macroeconomic cycles may adjust this trend.
Competitors of NeuroSense Therapeutics
BIIB (Biogen) - Projected Future Earnings|Net Profit Forecast NBIX (Neurocrine Biosciences, Inc.)|Projected Future Earnings RGC|Axsome Corp - Net Profit Forecast|Projected Future Earnings ACAD (ACADIA Corp)|XENE: Net Profit Forecast|Viking Therapeutics Inc - Projected Future Earnings|Expected Net Profit Supernus Pharmaceuticals, Inc.|Catalyst Pharmaceuticals Inc (CPRX) - Expected Profit|DNLI (Denali Therapeutics Inc) - Expected Profit|Expected Profit Harmony Biosciences Holdings, Inc.|Expected Profit BHVN|Future Profit AMLX (Amylyx Pharmaceuticals, Inc.)|Future Net Profit TRVI|Expected Profit Praxis Precision Medicines, Inc. PRAX|Anavex Corp - Expected Profit|CBLL: Future Profit|Expected Net Income PRTA (prothena.com)|Alector, Inc. (ALEC) - Expected Profit|Net Profit Forecast ANNX|Expected Profit Omeros Corp.|Neurogene Therapeutics (NGNE) - Company Profit Forecast|Projected Future Earnings ACIU|VYGR (Voyager Therapeutics) - Expected Net Income|Projected Future Earnings NMRA (neumoratx.com)|SCLX: Net Profit Forecast|TVGN - Expected Profit|Expected Net Profit Alpha Cognition Inc.|CGTX: Projected Future Earnings|inhibikase.com (IKT) - Projected Future Earnings|Expected Profit Cassava Sciences Inc|ASRT - Projected Net Profit|Expected Profit Coya (COYA)|Projected Future Earnings VistaGen Therapeutics Inc (VTGN)|Ovid Therapeutics Inc. - Future Profit|Company Profit Forecast Acumen Pharmaceuticals (ABOS)|CervoMed Corporation - Projected Future Earnings|Company Profit Forecast alteritytherapeutics.com ATHE|CLNN: Projected Future Earnings|Expected Net Profit PepGen Corp (PEPG)|Expected Profit Jupiter Neurosciences, Inc.|RLMD: Expected Net Income|Projected Future Earnings ANVS|Future Profit Grace Tx GRCE|Expected Profit Firefly Neuroscience, Inc AIFF|KLTO: Net Profit Forecast|RVPH: Future Profit|MTVA - Projected Future Earnings|NRXS (neuraxis.com) - Future Profit|Expected Net Profit Helius Medical Technologies Inc. (HSDT)|Expected Profit Passage Bio Corp|Future Profit Neuphoria Therapeutics (NEUP)|Projected Future Earnings NERV|ATHA - Expected Net Profit|Projected Future Earnings ADXN (addextherapeutics.com)|Alzamend (ALZN) - Expected Net Profit|CYCN: Future Profit|Expected Net Profit Protagenic Therapeutics Inc.|pasitheaclinics.com (KTTA) - Expected Profit|Expected Net Profit Cortigent Medical (CRGT)|ATXI (Avenue Therapeutics Inc) - Projected Future Earnings|BCLI (Brainstorm Cell Therapeutics Inc.) - Future Net Profit|Projected Future Earnings CARA|CHRO - Expected Net Profit|Eliem Therapeutics - Future Profit|Intra-Cellular (ITCI) - Expected Net Profit|LBPH - Expected Profit|MRNS - Projected Future Earnings|NKGN: Projected Future Earnings|NeuroBo Pharma (NRBO) - Projected Future Earnings|Future Profit SAGE|Net Profit Forecast SNPX (Synaptogenix, Inc.)|Expected Profit Trevena, Inc (TRVN)|VIGL (Vigil Neuroscience Inc.) - Expected Net Income|Expected Profit Anew Medical WENA|Future Net Profit CERE (Cerevel)
